15
views
0
recommends
+1 Recommend
1 collections
    0
    shares

          The flagship journal of the Society for Endocrinology. Learn more

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Normocalcaemic hyperparathyroidism and primary hyperparathyroidism: least significant change for adjusted serum calcium

      case-report

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction

          The least significant change (LSC) is a term used in individuals in order to evaluate whether one measurement has changed significantly from the previous one. It is widely used when assessing bone mineral density (BMD) scans. To the best of our knowledge, there no such estimate available in the literature for patients with disorders of calcium metabolism. Our aim was to provide an estimate of the least significant change for albumin-adjusted calcium in patients with normocalcaemic hyperparathyroidism (NPHPT) and primary hyperparathyroidism (PHPT).

          Methods

          We used the within-subject standard deviatio calculated in a population of NPHPT and PHPT patients and multiplied it by 2.77.

          Results

          The LSC for NPHPT and PHPT were found to be 0.25 and 0.24 mmol/L, respectively (1.00 and 0.96 mg/dL). In clinical practice, the value of 0.25 mmol/L could be used.

          Discussion

          The least significant change given, could be used in two ways in these patients. First, it gives a range to which values are expected. This can provide some reassurance for the patient and the physician in cases of intermittent hypercalcaemia. Moreover, it can be a marker of whether an individual has an actual significant change of his calcium after parathyroid surgery.

          Related collections

          Most cited references15

          • Record: found
          • Abstract: found
          • Article: not found

          Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop.

          Asymptomatic primary hyperparathyroidism (PHPT) is routinely encountered in clinical practices of endocrinology throughout the world. This report distills an update of current information about diagnostics, clinical features, and management of this disease into a set of revised guidelines.
            • Record: found
            • Abstract: not found
            • Article: not found

            Statistics Notes: Measurement error

              • Record: found
              • Abstract: found
              • Article: not found

              Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.

              Asymptomatic primary hyperparathyroidism (PHPT) is a common clinical problem. The purpose of this report is to provide an update on the use of diagnostic tests for this condition in clinical practice. This subgroup was constituted by the Steering Committee to address key questions related to the diagnosis of PHPT. Consensus was established at a closed meeting of the Expert Panel that followed. Each question was addressed by a relevant literature search (on PubMed), and the data were presented for discussion at the group meeting. Consensus was achieved by a group meeting. Statements were prepared by all authors, with comments relating to accuracy from the diagnosis subgroup and by representatives from the participating professional societies. We conclude that: 1) reference ranges should be established for serum PTH in vitamin D-replete healthy individuals; 2) second- and third-generation PTH assays are both helpful in the diagnosis of PHPT; 3) normocalcemic PHPT is a variant of the more common presentation of PHPT with hypercalcemia; 4) serum 25-hydroxyvitamin D concentrations should be measured and, if vitamin D insufficiency is present, it should be treated as part of any management course; 5) genetic testing has the potential to be useful in the differential diagnosis of familial hyperparathyroidism or hypercalcemia.

                Author and article information

                Journal
                Eur J Endocrinol
                Eur J Endocrinol
                EJE
                European Journal of Endocrinology
                Bioscientifica Ltd (Bristol )
                0804-4643
                1479-683X
                January 2021
                27 October 2020
                : 184
                : 1
                : K7-K10
                Affiliations
                [1 ]Department of Oncology and Metabolism , University of Sheffield, Sheffield, UK
                [2 ]School of Health and Related Research (ScHARR) , University of Sheffield, Sheffield, UK
                [3 ]Sheffield Teaching Hospitals National Health Service Foundation Trust (STH NHS FT) , Sheffield, UK
                Author notes
                Correspondence should be addressed to M Schini; Email: m.schini@ 123456sheffield.ac.uk
                Article
                EJE-20-0634
                10.1530/EJE-20-0634
                7707804
                33112283
                01fb39b1-2dec-4bef-b336-26df2e038390
                © 2021 The authors

                This work is licensed under a Creative Commons Attribution 4.0 International License.

                History
                : 08 June 2020
                : 27 October 2020
                Categories
                Brief Report

                Endocrinology & Diabetes
                Endocrinology & Diabetes

                Comments

                Comment on this article

                Related Documents Log